We therefore examined whether the mobilization and potential weakening of E-cadherin junctions observed in invasive pancreatic tumors of Pdx1-Cre; KrasG12D; p53R172H E-cadherin-GFP mice could be reverted using dasatinib. The gene discussed is PDX1; the disease is pancreatic neoplasm.